Selection of First-line Therapy in Advanced, Unresectable HCC

Download this slideset for expert perspectives on the optimal use of systemic therapy in the first-line setting for patients with advanced HCC.
Stacey Stein, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 959 KB
Released: January 23, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Eisai
Merck Sharp & Dohme Corp.

Related Content

From Clinical Care Options (CCO), download slides reviewing the integration of CAR T-cell therapy into community care

person default Jesús G. Berdeja, MD Caron A. Jacobson, MD Released: June 30, 2022

Data on dostarlimab for locally advanced, mismatch repair-deficient rectal cancer, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 14, 2022

Expanded results from CheckMate 648 of first-line nivolumab + chemotherapy or ipilimumab vs chemotherapy alone in advanced esophageal squamous cell cancer, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 13, 2022

CAIRO5: FOLFOXIRI + bevacizumab vs FOLFOX/FOLFIRI + bevacizumab in initially unresectable colorectal liver metastases, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 10, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings